Trends in PCSK9 Inhibitor Use After Price Reduction: A Real-World Analysis

This retrospective cohort study examined PCSK9 inhibitor prescription patterns among 1,059 patients at a single academic medical center before and after manufacturers negotiated price reductions for patients without adequate insurance coverage in 2018.

After price reductions (bringing net cost to patients to ~$250–450/month rather than ~$14,000/year list price), prescription rates increased and the payer-mix barrier — previously the dominant obstacle — became less dominant. However, medication adherence at 12 months remained lower than expected: a substantial proportion of patients who initiated PCSK9 inhibitor therapy did not refill prescriptions. Prior authorization requirements and prescriber uncertainty about patient eligibility remained significant barriers even after price reduction.

PCSK9 inhibitors reduce LDL-C by 50–60% on top of maximum statin therapy and reduce major cardiovascular events by ~15% in high-risk patients (Sabatine et al., 2017). But their clinical potential depends on consistent long-term use, and access barriers — cost, prior authorization burden, specialty prescribing patterns — have historically limited uptake. This study shows that price alone does not resolve the access problem.

For patients with established ASCVD, familial hypercholesterolemia, or inadequate LDL-C control on maximally tolerated statins with ezetimibe, PCSK9 inhibitors represent a guideline-recommended therapeutic option. The real-world gap between evidence and utilization remains substantial.

We rate the evidence limited. A single-center retrospective study providing useful real-world access and utilization data on PCSK9 inhibitors after price reduction — practically relevant but geographically limited.